I replied to a question in another thread which required me to...

I replied to a question in another thread which required me to do some more reading about pseudoprogression.

Pseudoprogression With Immunotherapy Treatment for Cancer (verywellhealth.com)
[7] The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy | Cancer Biology & Medicine (cancerbiomed.org)

With that in mind, even if we were given regular updates, they would almost be meaningless until 3-6 months after first treatment. So, I'm not overly concerned if we don't receive any further updates until there has been sufficient time for cohort 5 and/or even cohort 6 to have moved beyond pseudoprogression. (Which yes, will possibly be late this year if not early next year! I think best case scenario would be September/October this year.)

So, the next question that comes to mind is: Will we see pseudoprogression when onCARlytics is combined with Blincyto?
With some (very) quick research, I didn't find an answer however it seems pseudoprogression can occur with CAR-T treatments so maybe it will occur for Blincyto.

Obviously there's been a few hints that news will be coming soon, and the recent increase of investor presentations and investor marketing/communications from the company seems to serve as a bit of a look at us (and while you're looking, we'll drop some news), however, the news may not be for a CF33 related treatment. Not sure what to make of it all other than, drug development and clinical trials are not for the short term &/or impatient investor.